Mark Talamonti to Psoriasis
This is a "connection" page, showing publications Mark Talamonti has written about Psoriasis.
Connection Strength
4.388
-
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. J Eur Acad Dermatol Venereol. 2020 Dec; 34(12):e770-e772.
Score: 0.603
-
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020 01; 20(1):95-104.
Score: 0.572
-
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol. 2018 Oct; 32(10):1737-1744.
Score: 0.518
-
Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017 Aug; 177(2):489-496.
Score: 0.486
-
Brodalumab for the treatment of psoriasis. Expert Rev Clin Immunol. 2016 Dec; 12(12):1255-1271.
Score: 0.464
-
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis. Mol Diagn Ther. 2016 06; 20(3):227-30.
Score: 0.451
-
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013 Aug; 169(2):458-63.
Score: 0.371
-
Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension. Dermatology. 2011; 222(3):250-5.
Score: 0.316
-
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020 06; 20(6):665-672.
Score: 0.146
-
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020 Jan; 34(1):112-118.
Score: 0.141
-
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis. J Dermatolog Treat. 2017 Jun; 28(4):299-303.
Score: 0.116
-
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology. 2010; 221 Suppl 1:43-7.
Score: 0.075
-
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. Dermatology. 2009; 219(1):48-53.
Score: 0.069
-
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol. 2007 Apr; 156 Suppl 2:17-23.
Score: 0.060